The 6th Annual Roseman University Research Symposium is set to return to both the Henderson, NV and South Jordan, UT campuses on Wednesday, March 11. Over 150 abstracts were submitted from all three Roseman University campuses as well as colleagues from outside the University. Abstracts will again feature a range of topics in various areas including bench-top science, clinical research, and educational research. The university will host renowned experts in the field of antibiotic resistance (Henderson, NV) and targeted therapies for cancer, autoimmune and infectious diseases (South Jordan, UT).
Roseman University alum Ravina Kullar, PharmD, MPH, FIDSA, will present Antibiotic Resistance & The Post-Antibiotic Apocalypse: Can We Turn Back Time? for the Henderson campus keynote address. Since graduating from Roseman’s College of Pharmacy in 2007 and pursuing graduate education in research and infectious diseases, Dr. Kullar dedicated her career to finding solutions to antibiotic resistance.
Over the past decade, Dr. Kullar has emerged as an expert in the worldwide effort to address the growing crisis and even gave a talk at TEDxBlend on the subject. As she told spectRUm magazine last fall, “Unfortunately, much of the public believes that we have a surplus of antibiotics, but we don’t. We are currently living in the post-antibiotic era,” said Dr. Kullar. “Clinicians are responsible for this antibiotic resistance crisis via overusing antibiotics in their patients─ giving antibiotics to patients, ‘just because’ when there was no clear bacterial indication─ and the public is responsible for overuse of antibiotics when they are not necessary.”
Dr. Philip S. Low the Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry at Purdue University will present, New Targeted Therapies for Cancer Autoimmune and Infectious Diseases for the South Jordan campus keynote address. Dr. Low has devoted over 45 years to exploring novel drugs for treatment of human diseases, characterizing the structure of the human red blood cell membrane, and defining signal transduction pathways in plants.
He has published more than 450 scientific articles and has over 80 U.S. patents/patents pending. Eight drugs stemming from his research are undergoing human clinical trials in the areas of: i) tumor-targeted drugs for the imaging and therapy of cancer, ii) a new therapy for malaria, iii) a novel treatment for sickle cell disease, iv) tumor-targeted fluorescent dyes for image-guided surgery of cancer, and v) novel imaging and therapeutic agents for inflammatory and autoimmune diseases. Six companies have been founded to commercialize these discoveries.
Dr. Low has received a National Institutes of Health MERIT Award, the American Chemical Society’s Award for Cancer Research (Sosnovsky Award), the American Association for Cancer Research’s (AACR) Award for Outstanding Chemistry in Cancer Research, both of Purdue’s awards for outstanding research (McCoy and Sigma Xi Awards), the University’s highest career achievement award (Morrill Award), and numerous other National and International awards. Dr. Low received his B.S. in Chemistry from Brigham Young University (1971) and his Ph.D. in Biochemistry from University of California, San Diego (1975).
“So much of science is serendipity. You begin work with one specific goal in mind and then have an accidental finding or unexpected result that takes your work in a new, previously unimagined direction,” Dr. Low said. “This kind of science thrives when you have a large collaborative scientific environment, like we have at Purdue Center for Cancer Research.”
You learn more about the 6th Annual Roseman University Research Symposium visit https://www.roseman.edu/research-symposium/.
Marketing Communications Specialist